ALK-positive NSCLC (Exploratory analysis of pts with baseline brain metastases from two prospective studies): (1) phase I/II (NCT01449461) (2) phase II ATLA (NCT02094573) arm A (3) phase II ATLA (NCT02094573) arm B. Here, ALK is linked to non-small cell lung carcinoma.